Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDADiscover the Best Stocks and Maximize Your Portfolio: See ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

This means that the 1.7 million-plus global Dexcom users won't need to worry about their iPhone being with them and charged ...

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million. DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short. DexCom ...

7.9% per year. Even after the forecast slowdown in growth, it seems obvious that DexCom is also expected to grow faster than the wider industry.